Acceleron Is in Advanced Talks for $11 Billion Sale

Drugmaker Acceleron Pharma Inc. is in advanced discussions to be acquired by a large pharmaceutical company for about $180 a share in cash, according to people familiar with the matter.

The identity of the potential buyer couldn’t be immediately learned. Several global drugmakers, including Bristol-Myers Squibb Co., which owns 11.5% of Acceleron’s stock, are seen as obvious potential suitors, said the people, who asked not to be identified because the information was private.